iRadimed Corp (FRA:46K)

Q1 2026 IRadimed Corp Earnings Call Transcript

May 1, 2026 / 03:00 PM GMT

Release Date Price: €71

Transcript 10-Q8-K

Key Points

Positve

iRadimed Corp (IRMD) reported a 13% increase in revenue for Q1 2026, reaching $22 million compared to the same period in 2025.
The company achieved a 33% improvement in operating income, totaling $7.2 million, driven by disciplined expense management and a modified commission structure.
Net income rose by 22% to $5.8 million, or $0.45 per diluted share, showcasing strong financial performance.
The new 3,870 MR IV pump system is experiencing higher-than-expected ASP increases, with initial orders showing a 20% lift over the previous model.
iRadimed Corp (IRMD) is targeting a $50 million annual revenue run rate for pumps, with expectations of achieving a $100-plus million revenue run rate as 2026 progresses.

Negative

Revenue expectations for Q2 2026 are projected to be between $20 million to $21 million, indicating a potential decline from Q1 2026.
The company is facing challenges in ramping up production of the new 3,870 pump system, with a cautious approach to scaling manufacturing.
Despite strong initial interest, Q2 revenue will not fully reflect the high level of order activity due to production constraints.
The effective tax rate for the quarter increased to approximately 25%, influenced by the timing of deductions tied to equity grants.
The company anticipates a controlled revenue growth rather than a step change, with declining revenue from older pump systems offsetting new product sales.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IRMD.OQ - IRadimed Corp
Q1 2026 IRadimed Corp Earnings Call
May 01, 2026 / 03:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Eradimab Corporation's first quarter of 2026 financial results conference call. All participants are currently in listen-only mode. At the end of the call, we will conduct a question-and-answer session. This call is being recorded today, May 1, 2026, and contains time-sensitive accurate information that is valid only for today.

Earlier, Eradimab released its financial results for the first quarter of 2026. A copy of this press release announcing the company's earnings is available under the heading News on their website at aradamed.com.

A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at fcc.gov.

This call is being broadcast live on the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.